Shares of Retrophin (NASDAQ:RTRX) hit a new 52-week high and low during trading on Thursday . The company traded as low as $29.77 and last traded at $29.04, with a volume of 4094 shares traded. The stock had previously closed at $29.32.
RTRX has been the subject of a number of research reports. BMO Capital Markets reduced their price objective on Retrophin from $44.00 to $43.00 and set an “outperform” rating for the company in a research report on Wednesday, April 4th. ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research report on Monday, April 9th. Finally, BidaskClub upgraded Retrophin from a “hold” rating to a “buy” rating in a research report on Saturday, March 3rd.
Get Retrophin alerts:
The company has a quick ratio of 4.98, a current ratio of 5.07 and a debt-to-equity ratio of 0.15.
Retrophin (NASDAQ:RTRX) last posted its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.25). The company had revenue of $38.43 million for the quarter, compared to the consensus estimate of $39.32 million. Retrophin had a negative return on equity of 20.27% and a negative net margin of 41.95%. Retrophin’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.01 EPS. equities analysts predict that Retrophin will post -1.7 EPS for the current year.
Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP bought a new position in shares of Retrophin during the 1st quarter worth approximately $110,000. Xact Kapitalforvaltning AB bought a new position in shares of Retrophin during the 1st quarter worth approximately $206,000. Quantitative Systematic Strategies LLC bought a new position in shares of Retrophin during the 1st quarter worth approximately $245,000. Teacher Retirement System of Texas bought a new position in shares of Retrophin during the 4th quarter worth approximately $256,000. Finally, MetLife Investment Advisors LLC bought a new position in shares of Retrophin during the 4th quarter worth approximately $346,000.
Retrophin Company Profile
Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.